Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Omkar PharmachemBOM:532167 -4.97%52 Net Current Asset Value is ₹0.25 as of Mar. 2026, which is 100% below its 10-year median of 118.00. GuruFocus rates BOM:532167 with a GF Score™ of 52/100 and a GF Value™ of ₹23.90 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 629 Business Services companies, Omkar Pharmachem ranks worse than 97.14% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Omkar Pharmachem's net current asset value per share for the quarter that ended in Mar. 2026 was ₹0.25.
The historical rank and industry rank for Omkar Pharmachem's Net Current Asset Value or its related term are showing as below:
BOM:532167'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 60.36 Med: 118 Max: 333.33
Current: 60.36
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Omkar Pharmachem was 333.33. The lowest was 60.36. And the median was 118.00.
BOM:532167's Price-to-Net-Current-Asset-Value is ranked worse than 97.14% of 629
companies
in the Business Services industry
Industry Median: 3.88
vs BOM:532167: 60.36
Omkar Pharmachem (BOM:532167) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Omkar Pharmachem Net Current Asset Value Related Terms
Omkar Pharmachem Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Omkar Pharmachem's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:532167 vs CTAS, CPRT, GPN: Net Current Asset Value Comparison
For the Specialty Business Services subindustry, Omkar Pharmachem's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omkar Pharmachem Price-to-Net-Current-Asset-Value vs Business Services Industry
For the Business Services industry and Industrials sector, Omkar Pharmachem's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Omkar Pharmachem's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ₹0.25 mean?
Omkar Pharmachem (BOM:532167) has a Net Current Asset Value of ₹0.25 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Omkar Pharmachem and its competitors. This is 100% below median its historical median of 118.00. Over the past decade, Omkar Pharmachem's Net Current Asset Value has ranged from 60.36 to 333.33. According to the industry distribution chart, Omkar Pharmachem ranks #611 out of 629 companies in the Business Services industry, placing it in the top 97.1%.
Is Omkar Pharmachem's Net Current Asset Value too high?
Omkar Pharmachem's current Net Current Asset Value of ₹0.25 is 100% below median its 10-year median of 118.00. Over the past 10 years, this metric has ranged from a low of 60.36 to a high of 333.33. Based on the distribution chart, Omkar Pharmachem ranks #611 out of 629 companies in the Business Services industry, which is in the bottom quartile relative to peers. Overall, Omkar Pharmachem has a GF Score™ of 52/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Omkar Pharmachem's Net Current Asset Value compare to CTAS and CPRT?
According to the Business Services industry distribution chart, Omkar Pharmachem ranks #611 out of 629 companies for Net Current Asset Value. This places Omkar Pharmachem in the lower half of its industry. The industry median Net Current Asset Value is 3.88. Historically, Omkar Pharmachem's own Net Current Asset Value has ranged from 60.36 to 333.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Business Services company?
The median Net Current Asset Value among Business Services companies is 3.88, based on 629 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Omkar Pharmachem and its competitors. For the Business Services industry, the median Net Current Asset Value is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omkar Pharmachem's current Net Current Asset Value is ₹0.25, which is 100% below median its own 10-year median of 118.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omkar Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Omkar Pharmachem (BOM:532167) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹23.90, compared to a current price of ₹15.09 — trading 36.9% below its estimated fair value. The current Net Current Asset Value is ₹0.25, which is 100% below median its 10-year median of 118.00. Omkar Pharmachem's overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Omkar Pharmachem (BOM:532167), the current Net Current Asset Value is ₹0.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Omkar Pharmachem (BOM:532167) Overvalued in 2026?
Based on GuruFocus' analysis, Omkar Pharmachem stock appears to be undervalued.
The current stock price of ₹15.09 is trading 36.9% below its estimated GF Value™ of ₹23.90.
GuruFocus considers Omkar Pharmachem to be Significantly Undervalued.
Key valuation signals for BOM:532167:
Net Current Asset Value: ₹0.25 (100% below median its 10-year median of 118.00)
GF Value™: ₹23.90 vs. price of ₹15.09 (36.9% below fair value)
No single metric tells the full story. See the BOM:532167 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532167 has been successfully added to your 
